IPO

In February, biotechnology company Beam Therapeutics Inc closed its initial public offering (IPO) of 12,176,471 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,588,235 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Beam … Read more

U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures … Read more

Inhibrx, Inc is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx uses diverse methods of protein engineering to address the specific requirements of target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. The company has … Read more

Harmony Biosciences is a private pharmaceutical company based in Plymouth Meeting, PA. Established in October 2017, the company’s vision is to develop and provide new medications to help people who are living with rare, neurological diseases. In October 2017, the company acquired exclusive U.S. rights to develop, register and market the drug pitolisant (WAKIX) from … Read more

Panacea Acquisition is a special type of holding company designed to acquire operating companies in the biotechnology space. As a special purpose holding company (SPAC), the company has no operations other than a plan to go public with the intention of acquiring or merging with a company using the proceeds of its initial public offering … Read more

Freeline Therapeutics is a UK-based biotechnology company that develops liver-directed gene therapies for bleeding disorders and other diseases. Its therapies are based on a next-generation proprietary AAV vector platform, specifically a gene therapy to treat haemophilia B. The company plans to raise $125 million by offering 7.4 million ADSs at a price range of $16 … Read more

It all began with an unexpected discovery. CureVac’s founder, Dr. Ingmar Hoerr (a doctoral student at the time), discovered that when it was administered directly into tissue, the historically unstable biomolecule mRNA could be used as a therapeutic vaccine or agent after optimization—no complicated reformulations or molecular packaging needed. With a single discovery, CureVac opened … Read more

iTeos, a Cambridge, MA-based company, plans to raise $151 million by offering 8.9 million shares at a price range of $16-$18. Its fully-diluted market cap would be $579 million at the midpoint of the proposed price range. iTeos a clinical-stage biopharmaceutical company focusing on the discovery and development of a new generation of immuno-oncology therapeutics. … Read more

Relay Therapeutics is a clinical-stage precision medicines company innovating in the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company leverages insights into protein motion and how this dynamic behavior relates to protein function. These insights may enable Relay to more effectively drug protein targets that … Read more

In June, Repare Therapeutics Inc (RPTX) raised $220 million by offering 11 million shares at $20, the high end of the upwardly revised range of $18 to $20. Repare is a pre-clinical biotech company developing gene therapies for solid tumors based on a synthetic lethality (SL) approach to drug development. The company has advanced a … Read more